US compounding pharmacy switched suppliers mid-cycle and cleared a backlog of GLP-1 prescriptions in 5 weeks
A US Northeast 503A compounding pharmacy was losing patient throughput when its previous bulk-active supplier missed three consecutive lead-time commitments. Switching to PeptideXpo against a 6-month forecast cleared the backlog and stabilised the dispensing schedule.
Published May 14, 2026 · Anonymized customer story
Stockouts in 12 months post-switch
0
Backlog clearance time
~5 weeks
First reply from regulatory team
Within 12-hour SLA
Forecast horizon
6 months
Challenge
The pharmacy's existing supplier, a major US-based distributor for Chinese-manufactured peptide actives, had missed three consecutive lead-time commitments on Tirzepatide and Semaglutide bulk material across Q1 and Q2. Each miss cascaded into a 2-3 week dispensing backlog because the pharmacy had no in-house safety stock and the prescription queue kept building. The Director of Procurement faced two choices: switch suppliers mid-cycle (expensive, risky, requires re-qualification under state-board procedures) or accept the throughput loss and the patient-experience damage.
Approach
PeptideXpo's regulatory team responded to the initial RFQ within the published 12-hour SLA window and provided sample-batch COAs for Tirzepatide and Semaglutide alongside the quote. The pharmacy's in-house QC validated the sample-batch documentation (HPLC chromatograms, ESI mass spec, water content, counter-ion confirmation, LAL endotoxin) against the previous supplier's reference batch and accepted the qualification within 5 business days. A 6-month forecast was put in place at the same time, with PeptideXpo holding released-batch inventory against the forecast to compress effective lead time on each release to next-available-shipment.
Outcome
The dispensing backlog cleared in roughly 5 weeks once the forecast inventory was in place. Per-mg cost on Tirzepatide came in at the lower end of the typical US-market range because of the recurring-order pricing tier. The pharmacy reported zero stockouts in the 12 months following the supplier switch, and the forecast model held against shifting patient demand without requiring renegotiation.
“We went from three missed shipments in two quarters to zero stockouts in twelve months. The first reply from the regulatory team landed inside their published SLA, which is what we needed to make the case to our state-board compliance team for the mid-cycle switch.”